14-3-3 testing in diagnosing Creutzfeldt-Jakob disease: a prospective study in 112 patients

Neurology. 2000 Aug 22;55(4):514-6. doi: 10.1212/wnl.55.4.514.

Abstract

Objective: To study the sensitivity and specificity of 14-3-3 testing in a prospective series of patients suspected of having Creutzfeldt-Jakob disease (CJD).

Background: The 14-3-3 protein immunoassay on CSF has favorable test characteristics as a premortem diagnostic tool in CJD. However, the 14-3-3 protein is a normal cellular protein expressed in various tissues, and its presence in CSF reflects extensive destruction of brain tissue as in CJD, but also in ischemic stroke and meningoencephalitis.

Methods: 14-3-3 was tested in the CSF of a prospective series of 110 consecutive patients suspected of having CJD.

Results: The sensitivity was 97% and the specificity was 87% in this series. False-positive results were mainly caused by stroke and meningoencephalitis.

Conclusion: The 14-3-3 protein is a highly sensitive and specific marker for CJD when used in the appropriate clinical context.

Publication types

  • Clinical Trial

MeSH terms

  • 14-3-3 Proteins
  • Adult
  • Aged
  • Astrocytoma / cerebrospinal fluid
  • Astrocytoma / diagnosis*
  • Biomarkers / cerebrospinal fluid
  • Brain Diseases / cerebrospinal fluid
  • Brain Diseases / diagnosis
  • Brain Neoplasms / cerebrospinal fluid
  • Brain Neoplasms / diagnosis*
  • Cerebrospinal Fluid / chemistry
  • Creutzfeldt-Jakob Syndrome / cerebrospinal fluid
  • Creutzfeldt-Jakob Syndrome / diagnosis*
  • Diagnosis, Differential
  • False Positive Reactions
  • Female
  • Humans
  • Lymphoma / cerebrospinal fluid
  • Lymphoma / diagnosis*
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Prospective Studies
  • Proteins / analysis*
  • Sensitivity and Specificity
  • Tyrosine 3-Monooxygenase*

Substances

  • 14-3-3 Proteins
  • Biomarkers
  • Proteins
  • Tyrosine 3-Monooxygenase